Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

HISTORICAL FACTS: 14 - The Untold Story

Eli Lilly's Quarterly Earnings Preview: What You Need to Know

Eli Lilly is scheduled to report its first-quarter results next month, and analysts expect a significant double-digit earnings growth.

Barchart

Swiss drugmaker Roche to invest $50bn in US in effort to dodge Trump tariffs

Company says it will create 12,000 jobs in manufacturing and R&D over next five years

The Guardian - UK

Goldman Sachs Just Upgraded This Blue-Chip Stock. Should You Buy It Now?

With a strong pipeline, this pharmaceutical powerhouse is positioning itself as a dominant force in the future of medicine.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Daily weight-loss pill may work as well as Ozempic and could replace injections

Patients in a trial taking orforglipron lost an average of 7.2kg over nine months

The Independent UK

New daily weight-loss pill shows success at clinical trial

Orforglipron also reduced blood sugar levels in participants with type 2 diabetes

The Guardian - UK

Experimental daily pill found to aid weight loss in what could be alternative to jabs like Ozempic

Other weight loss drugs must be injected, meaning the new pill from pharmaceutical giant Eli Lilly could become patients’ top choice if it is approved.

Euronews

Analysts Love These 2 Stocks to Buy for Q2

Investors could snag these two stocks as BofA flags the companies as well-positioned winners in an uncertain quarter.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Hims’ Weight Loss Expansion: Real Growth or Just Hype?

Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite?

MarketBeat

Experimental Drug Shows Promise In Eliminating Hard-To-Treat Deadly Cholesterol

A single dose of lepodisiran dramatically lowered dangerous lipoprotein(a) levels for up to a year, offering new hope for heart disease treatment.

Medical Daily

Novo Nordisk shares post the biggest monthly decline since 2002

Novo Nordisk’s stocks experienced the sharpest monthly decline since July 2002 due to growing competition and several disappointing trial results. However, analysts remain optimistic about the shares, forecasting a potential price upside of up to 60% over the next 12 months.

Euronews

Who should avoid taking viral drug Mounjaro? Expert explains

Eli Lilly's recent launch of Mounjaro (tirzepatide) in India has sparked significant interest especially among those looking for weight loss and diabetes control.

The Times of India

European committee says Lilly Alzheimer's drug shouldn't get marketing approval

A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling

The Independent UK

EU regulators block new Alzheimer’s drug citing potentially fatal side effects

The company behind the drug donanemab said it will ask regulators to reconsider the decision.

Euronews

Tariff treatment: Six diagnoses for EU pharma sector amid US trade war

Potential US tariffs on pharmaceuticals could set off a ripple effect that extends far beyond the immediate price hikes, as both the US and Europe heavily rely on each other.

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Price Targets Show These 3 Stocks Near the $1 Trillion Mark

See what analysts' price targets say about the prospects of these three stocks flirting with the $1 trillion valuation mark.

inkl

How Diabetes Patients Are Fighting for Affordable Insulin

The World Health Organization states that there were around 830 million people living with diabetes in 2022. More than half of them weren't taking diabetes medications, including insulin, likely due to access and cost issues.

The Times of India

Mounjaro: As Eli Lilly's blockbuster anti-obesity drug comes to India, expert lists key side effects

Eli Lilly's blockbuster drug 'Mounjaro' was launched in India on Thursday. The pharma manufacturer said it has launched a first-of-its-kind medication for obesity and type 2 diabetes in the country after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). The company said it has introduced Mounjaro in a…

Barchart

Is Amgen Stock a Buy, Sell, or Hold as Weight-Loss Drug Trials Kick Off?

Amgen is hoping to rival Novo Nordisk and Eli Lilly in the weight-loss drug market.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors

Pharma giant Eli Lilly announced plans to make a massive investment in the United States. What does this and another big announcement mean for Lilly?

The Independent UK

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance

Barchart

Is Johnson & Johnson Stock Underperforming the Dow?

Despite Johnson & Johnson’s underperformance relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outperformed the Nasdaq over the past year, and analysts are highly optimistic about the stock’s prospects.

Barchart

Is This Penny Stock’s 525% Upside Potential an Attainable Goal?

Skye Bioscience is trying to establish a presence in the weight-loss drug market.

StockNews.com

3 Pharmaceutical Stocks Betting Big on Weight Loss Drugs

Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, pharmaceutical giants like Eli Lilly and Company (LLY), Novo Nordisk (NVO), and Amgen (AMGN) are betting big on next-generation weight loss treatments to dominate this booming market. Keeping reading.

Fortune

Weight-loss drug Zepbound helped Ireland ship $76bn in goods to the U.S.

Ireland's pharmaceutical industry shipped billions' worth of goods to the U.S., but face threats from Trump 2.0.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.